This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
近の日本の疫学調査では,外来で抗ウイルス薬治療を受けた患者の 12.4%が 90日後に,4.0%が 360日後に疼痛が残存していた.高齢者,初診時の皮疹や疼痛が重症な群では疼痛残存率が上昇する傾向にあった 8).PHNに関わらず,帯状疱疹の痛みは患者 QOLを低下させる.フランスでの9038名の帯状疱疹患者(急性期痛 8013名,PHN935名)を Medical Outcome Study Short Form 36 (MOS SF 36)を用いて QOLを調べた調査では,急性期痛,PHNとも様々な尺度で QOLの低下がみられた 9).
10) Takahashi M, Otsuka T, Okuno Y, Asano Y, Yazaki T. Live vaccine used to prevent the spread of varicella in children in hospital. Lancet 1974;2:1288-90.
tion of links between herpes zoster incidence and childhood varicella vaccination. Ann Intern Med 2013;159:739-45.
13) Goldman GS, King PG. Review of the United States universal varicella vaccination program: Herpes zos-ter incidence rates, cost-effectiveness, and vaccine efficacy based primarily on the Antelope Valley Vari-cella Active Surveillance Project data. Vaccine. 2013; 31:1680-94.
15) Okuno Y, Takao Y, Miyazaki Y, Ohnishi F, Okeda M, Yano S, Kumihashi H, Gomi Y, Maeda K, Ishikawa T, Mori Y, Asada H, Iso H, Yamanishi K; Shozu Herpes Zoster (SHEZ) Study Group. Assessment of skin test with varicella-zoster virus antigen for predicting the risk of herpes zoster. Epidemiol Infect 2013; 141:706-13.
16) Asada H, Nagayama K, Okazaki A, Mori Y, Okuno Y, Takao Y, Miyazaki Y, Onishi F, Okeda M, Yano S, Kumihashi H, Gomi Y, Maeda K, Ishikawa T, Iso H, Yamanishi K; Shozu Herpes Zoster (SHEZ) Study group. An inverse correlation of VZV skin-test reac-tion, but not antibody, with severity of herpes zoster skin symptoms and zoster-associated pain. J Dermatol Sci 2013;69:243-49.
17) Imoto K, Okazaki A, Onishi F, Miyazaki Y, Okeda M, Yano S, Takao Y, Gomi Y, Ishikawa T, Okuno Y, Mori Y, Iso H, Yamanishi K, Asada H; SHEZ study group. VZV skin-test reaction, but not antibody, is an important predictive factor for postherpetic neuralgia. J Derma-tol Sci 2015; 79:235-40.
18) Takahashi M, Okada S, Miyagawa H, Amo K, Yoshika-wa K, Asada H, Kamiya H, Torigoe S, Asano Y, Ozaki T, Terada K, Muraki R, Higa K, Iwasaki H, Akiyama M, Takamizawa A, Shiraki K, Yanagi K, Yamanishi K. Enhancement of immunity against VZV by giving live varicella vaccine to the elderly assessed by VZV skin test and IAHA, gpELISA antibody assay. Vaccine 2003; 21:3845-53.
19) Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, Arbeit RD, Simberkoff MS, Ger-shon AA, Davis LE, Weinberg A, Boardman KD, Wil-liams HM, Zhang JH, Peduzzi PN, Beisel CE, Morrison VA, Guatelli JC, Brooks PA, Kauffman CA, Pachucki CT, Neuzil KM, Betts RF, Wright PF, Griffin MR, Brunell P, Soto NE, Marques AR, Keay SK, Goodman RP, Cotton DJ, Gnann JW Jr, Loutit J, Holodniy M, Kei-tel WA, Crawford GE, Yeh SS, Lobo Z, Toney JF, Greenberg RN, Keller PM, Harbecke R, Hayward AR, Irwin MR, Kyriakides TC, Chan CY, Chan IS, Wang WW, Annunziato PW, Silber JL; Shingles Prevention Study Group. A vaccine to prevent herpes zoster and
2 ) Toyama N, Shiraki K; Society of the Miyazaki Prefec-ture Dermatologists. Epidemiology of herpes zoster and its relationship to varicella in Japan: A 10-year survey of 48,388 herpes zoster cases in Miyazaki pre-fecture. J Med Virol 2009;81:2053-8.
3 ) Weinberg JM. Herpes zoster: epidemiology, natural history, and common complications. J Am Acad Der-matol. 2007;57:S130-5.
4 ) Hata A, Kuniyoshi M, Ohkusa Y. Risk of Herpes zoster in patients with underlying diseases: a retrospective hospital-based cohort study. Infection 2011;39:537-44.
5 ) Habel LA, Ray GT, Silverberg MJ, Horberg MA, Yawn BP, Castillo AL, Quesenberry CP Jr, Li Y, Sadier P, Tran TN. The epidemiology of herpes zoster in patients with newly diagnosed cancer. Cancer Epide-miol Biomarkers Prev 2013;22:82-90.
6 ) 渡辺大輔.グラフ 帯状疱疹の合併症のサイン 週間医事新報 2013;4672:18-20.
7 ) Imafuku S, Nakayama J, Higa K, Furue M, Takahara M, Katayama I, Tani M. One-year follow-up of zoster-associated pain in 764 immunocompetent patients with acute herpes zoster treated with famciclovir (FAMILIAR study). J Eur Acad Dermatol Venereol 2014; 28:1716-22.
8 ) Chidiac C, Bruxelle J, Daures JP, Hoang-Xuan T, Morel P, Leplège A, El Hasnaoui A, de Labareyre C. Charac-teristics of patients with herpes zoster on presenta-tion to practitioners in France. Clin Infect Dis 2001; 33:62-69.
9 ) Langan SM, Minassian C, Smeeth L, Thomas SL. Risk of stroke following herpes zoster: a self-controlled case-series study. Clin Infect Dis 2014;58:1497-503.
29pp.21-30,2018〕
A, Puig-Barberà J, Vesikari T, Watanabe D, Weckx L, Zahaf T, Heineman TC; ZOE-50 Study Group. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med2015; 372: 2087-96.
25) Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang SJ, Díez-Domingo J, Godeaux O, Levin MJ, McElhaney JE, Puig-Barberà J, Vanden Abeele C, Vesikari T, Wata-nabe D, Zahaf T, Ahonen A, Athan E, Barba-Gomez JF1, Campora L, de Looze F, Downey HJ, Ghesquiere W, Gorfinkel I, Korhonen T, Leung E, McNeil SA, Oostvogels L, Rombo L, Smetana J, Weckx L, Yeo W, Heineman TC; ZOE-70 Study Group. Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older.N Engl J Med 2016; 375:1019-32.
27) Dooling KL, Guo A, Patel M, Lee GM, Moore K, Belon-gia EA, Harpaz R,. Recommendations of the Advisory Committee on Immunization Practices for Use of Her-pes Zoster Vaccines. MMWR Morb Mortal Wkly Rep 2018;67:103–108.
postherpetic neuralgia in older adults. N Engl J Med 2005; 352:2271-2284.
20) Oxman MN, Levin MJ; Shingles Prevention Study Group: Vaccination against Herpes Zoster and Postherpetic Neuralgia. J Infect Dis. 2008;197 Suppl 2:S228-36.
21) Schmader KE, Levin MJ, Gnann JW Jr, McNeil SA, Vesikari T, Betts RF, Keay S, Stek JE, Bundick ND, Su SC, Zhao Y, Li X, Chan IS, Annunziato PW, Parrino J. Efficacy, safety, and tolerability of herpes zoster vac-cine in persons aged 50-59 years. Clin Infect Dis 2012; 54:922-8.
22) Berkowitz EM, Moyle G, Stellbrink HJ, Schürmann D, Kegg S, Stoll M, El Idrissi M, Oostvogels L, Heineman TC; Zoster-015 HZ/su Study Group. Safety and immu-nogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled study. J Infect Dis 2015; 211:1279-87.
23) Chlibek R, Smetana J, Pauksens K, Rombo L, Van den Hoek JA, Richardus JH, Plassmann G, Schwarz TF, Ledent E, Heineman TC. Safety and immunogenicity of three different formulations of an adjuvanted vari-cella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study. Vac-cine 2014; 32:1745-53.
24) Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang SJ, Levin MJ, McElhaney JE, Poder
30
Herpes Zoster Vaccine
Daisuke WATANABE
Department of Dermatology, Aichi Medical University1-1 Yazakokarimata, Nagakute, Aichi, 480-1195, Japan
Herpes zoster, or shingles, results from the reactivation of latent varicella– zoster virus (VZV) in the dorsal-root or cranial-nerve ganglia, usually decades after primary infection. Herpes zoster is characterized by a vesicular rash with a unilateral and dermatomal distribution and is almost always accompanied by pain. Herpes zoster is not only skin disease, but also sometimes affects other organs, including central nerve system, eye, and facial nerve. The most common complications, such as postherpetic neuralgia (PHN), are more frequent, severe and impair patients’ quality of life. For more than 10 years, in US, EU, and Australia, a live-attenuated vaccine against herpes zoster (Zostavax) containing the Oka VZV strain is licensed for use in adults who are 50 years of age or older. In Japan, a live attenuated varicella vaccine is also licensed for preventing herpes zoster in 2016. Two large randomized multinational efficacy trials (ZOE-50 and ZOE-70) showed that the novel herpes zoster subunit vaccine (shinglix) candidate containing varicella-zoster virus glycoprotein E (gE) and the AS01B adjuvant system reduced the risk of herpes zoster and PHN by more than 90%. This article aimed to review the epidemiology, pathophysiology and complications of herpes zoster and mention the efficacies and problems of the live-attenuated and the new recombinant herpes zoster vaccines.